Mel Mann: Gleevec’s Anniversary

Mel Mann, Patient Advocate in Oncology and cancer survivor, shared on LinkedIn:

”Gleevec’s Anniversary.

On 10 May 2001, Gleevec (Imatinib) was approved by the FDA for use in Chronic Myeloid Leukemia (CML) and made the cover of TIME Magazine. It now works for 11 different types of cancer.

I was blessed to enter the Gleevec phase 1 clinical trial when it began 3 years prior, in 1998, and I became the World’s Longest Living Gleevec Survivor. When I was first diagnosed, I was given 3 years to live. However, I was able to get ‘Today’s medicine Yesterday,’ and that 3 years became 30 years. Clinical Trials are a way of getting ‘Tomorrow’s Medicine Today.”’

Source: Mel Mann/LinkedIn